Incyte (INCY) Gross Profit Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.21% |
| Dec 31, 2025 | 12.97% |
| Sep 30, 2025 | 16.66% |
| Jun 30, 2025 | 11.67% |
| Mar 31, 2025 | 12.60% |
| Dec 31, 2024 | 14.78% |
| Sep 30, 2024 | 15.06% |
| Jun 30, 2024 | 14.08% |
| Mar 31, 2024 | 11.52% |
| Dec 31, 2023 | 13.45% |
| Sep 30, 2023 | 15.12% |
| Jun 30, 2023 | 12.28% |
| Mar 31, 2023 | 15.60% |
| Dec 31, 2022 | 15.51% |
| Sep 30, 2022 | 16.42% |
| Jun 30, 2022 | 22.96% |
| Mar 31, 2022 | 13.34% |
| Dec 31, 2021 | 21.69% |
| Sep 30, 2021 | 25.41% |
| Jun 30, 2021 | 23.34% |
| Mar 31, 2021 | 17.45% |
| Dec 31, 2020 | 26.32% |
| Sep 30, 2020 | 26.70% |
| Jun 30, 2020 | 33.10% |
| Mar 31, 2020 | 28.20% |
| Dec 31, 2019 | 35.11% |
| Sep 30, 2019 | 21.38% |
| Jun 30, 2019 | 38.17% |
| Mar 31, 2019 | 39.61% |
| Dec 31, 2018 | 38.96% |
| Sep 30, 2018 | 37.98% |
| Jun 30, 2018 | 37.37% |
| Mar 31, 2018 | 38.71% |
| Dec 31, 2017 | 29.97% |
| Sep 30, 2017 | 42.84% |
| Jun 30, 2017 | 28.76% |
| Mar 31, 2017 | 59.15% |
| Dec 31, 2016 | 60.42% |
| Sep 30, 2016 | 71.54% |
| Jun 30, 2016 | 69.36% |
| Mar 31, 2016 | 52.43% |
| Dec 31, 2015 | 22.21% |
| Sep 30, 2015 | 60.74% |
| Jun 30, 2015 | 25.82% |
| Mar 31, 2015 | 55.53% |